Trinity Biotech (NASDAQ:TRIB) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research note released on Friday morning. The brokerage issued a hold rating on the stock.

Trinity Biotech Price Performance

NASDAQ:TRIB opened at $0.76 on Friday. Trinity Biotech has a 12-month low of $0.74 and a 12-month high of $3.55. The firm has a 50-day moving average price of $0.87 and a 200 day moving average price of $1.45.

Institutional Trading of Trinity Biotech

A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC increased its stake in shares of Trinity Biotech plc (NASDAQ:TRIB) by 5.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 378,590 shares of the company’s stock after purchasing an additional 18,780 shares during the quarter. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 at the end of the most recent quarter. Institutional investors and hedge funds own 78.97% of the company’s stock.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.